Pfizer fails to end lawsuit over Bextra, Celebrex safety
March 28 (Reuters) - Pfizer Inc has failed to persuade a federal judge to dismiss a shareholder lawsuit accusing the company of fraudulently misrepresenting the cardiovascular risks associated with its Bextra and Celebrex pain-relieving drugs.
While dismissing some of the shareholders' claims, U.S. District Judge Laura Taylor Swain in Manhattan said it was premature to dismiss the entire case.
Swain said a reasonable jury could find that Pfizer intended to mislead shareholders through its disclosures about the drugs' safety.
The plaintiffs are led by the Teachers' Retirement System of Louisiana, and a class was certified on July 5, 2012.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Last-minute Obamacare exemption for those with canceled plans
- Target cyber breach hits 40 million payment cards at holiday peak |
- U.S. diplomats, but not prosecutors, seek to quell India dispute |
- New York Mayor-elect's reputation for lateness parodied on Twitter